Needham & Company LLC restated their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV - Free Report) in a report issued on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $23.00 target price on the stock.
Separately, HC Wainwright started coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They issued a "buy" rating and a $20.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $20.40.
Check Out Our Latest Stock Analysis on Artiva Biotherapeutics
Artiva Biotherapeutics Trading Down 10.7 %
Shares of NASDAQ:ARTV traded down $0.38 during trading on Tuesday, reaching $3.16. The company had a trading volume of 80,335 shares, compared to its average volume of 114,168. Artiva Biotherapeutics has a fifty-two week low of $3.15 and a fifty-two week high of $17.31. The stock's fifty day moving average price is $4.71 and its 200 day moving average price is $9.21.
Institutional Trading of Artiva Biotherapeutics
A number of large investors have recently made changes to their positions in the stock. State Street Corp acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $1,337,000. Geode Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the third quarter worth approximately $4,774,000. Barclays PLC purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth approximately $304,000. BNP Paribas Financial Markets purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $42,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth $166,000.
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Recommended Stories
Before you consider Artiva Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artiva Biotherapeutics wasn't on the list.
While Artiva Biotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
